SARS-CoV-2 Infection in Patients Treated with Azacitidine and Venetoclax for Acute Leukemia: A Report of a Case Series Treated in a Single Institution
Conclusion: COVID-19 constitutes a frequent complication of AZA-VEN treatment in the era of the COVID-19 pandemic, leading to death in a significant proportion of patients.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - September 14, 2022 Category: Cancer & Oncology Source Type: research
SARS-CoV-2 Infection in Patients Treated with Azacitidine and Venetoclax for Acute Leukemia: A Report of a Case Series Treated in a Single Institution
Conclusion: COVID-19 constitutes a frequent complication of AZA-VEN treatment in the era of the COVID-19 pandemic, leading to death in a significant proportion of patients. (Source: Chemotherapy)
Source: Chemotherapy - September 14, 2022 Category: Cancer & Oncology Source Type: research
SARS-CoV-2 infection in patients treated with azacitidine and venetoclax for acute leukemia – a report of a case series treated in a single institution
Conclusion COVID-19 constitutes a frequent complication o f AZA-VEN treatment in the era of the COVID-19 pandemic leading to death in a significant proportion of patients. (Source: Chemotherapy)
Source: Chemotherapy - September 14, 2022 Category: Cancer & Oncology Source Type: research
MIC Discrepancies between Parenteral and Oral Anti-Staphylococcal Beta-Lactams among MSSA
Conclusions: The variations in MICs observed compounded with the dosing and pharmacokinetic differences of oral versus IV β-lactam suggests that establishing breakpoints for oral β-lactam antibiotics is necessary to ensure adequate therapy is selected for the treatment of complexS. aureus infections. (Source: Chemotherapy)
Source: Chemotherapy - August 24, 2022 Category: Cancer & Oncology Source Type: research
MIC discrepancies between parenteral and oral anti-staphylococcal β-lactams among MSSA
Conclusions: The variations in MICs observed compounded with the dosing and pharmacokine tic differences of oral vs IV β-lactam suggests that establishing breakpoints for oral β-lactam antibiotics is necessary to ensure adequate therapy is selected for the treatment of complex S. aureus infections. (Source: Chemotherapy)
Source: Chemotherapy - August 24, 2022 Category: Cancer & Oncology Source Type: research
Safety Signal between Azacitidine and Pericarditis
Conclusion: The signal between Azacitidine and pericarditis was found to be statistically significant. Clinicians should be aware of the possible risk of pericarditis when prescribing Azacitidine. If there is suspicion for Azacitidine induced pericarditis, clinicians should consider discontinuation of Azacitidine to improve patient ’s symptoms and reduce the likelihood of the development of constrictive pericarditis, pericardial effusion and cardiac tamponade. (Source: Chemotherapy)
Source: Chemotherapy - August 18, 2022 Category: Cancer & Oncology Source Type: research
Curcumin Suppresses the Progression of Colorectal Cancer by Improving Immunogenic Cell Death Caused by Irinotecan
Conclusion: Combination therapy with IRI and CUR may be an option for first-line chemotherapy in some patients with advanced colorectal cancer.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - July 27, 2022 Category: Cancer & Oncology Source Type: research
Treatment Tolerance of Cetuximab versus Alternative Chemotherapy Agents in Non-Cisplatin Candidates with Head and Neck Cancer Receiving Concurrent Chemoradiotherapy
Abstract
Introduction: Standard of care for radiosensitization in head and neck squamous cell carcinoma (HNSCC) is concurrent chemoradiotherapy (CCRT) with high-dose cisplatin. The optimal chemoradiation regimen for patients medically unfit for cisplatin is unclear. We compared our experience with concurre nt cetuximab versus other cytotoxic non-cisplatin agents.
Methods: We reviewed 53 patients between 2011 and 2017 with HNSCC treated with CCRT ineligible for cisplatin. Chemotherapy and radiotherapy treatment tolerance was evaluated in those receiving cetuximab (CTX) versus non-cetuximab chemotherap y (NCC). Of the NCC...
Source: Chemotherapy - July 26, 2022 Category: Cancer & Oncology Source Type: research
Fusidic acid and its major active metabolite penetration into cerebrospinal fluid for assessing treatment of intracranial infections.
Fusidic acid (FA) had the excellent antimicrobial effects due to its unique mechanism of action. Since 1962, FA has been widely used in the systemic and topical treatment of staphylococcal infections, and exhibit a well characterized potency against methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant coagulase negative Staphylococci
(MRCoNS). In view of the spectrum of activity, no cross-resistance with other clinically used antibiotics, and potential penetration into brain tissue, FA was used to treat possible gram-positive bacteria in three p...
Source: Chemotherapy - July 8, 2022 Category: Cancer & Oncology Source Type: research
Lung Adenocarcinoma Harboring Triple Rare EGFR Exon 18 Mutations Rapidly Developed Resistance to Multiple Therapies
There is no standard therapy for nonsmall-cell lung cancer harboring rare coexistent EGFR mutations. Here, we report a female patient who was diagnosed as lung adenocarcinoma with three mutations of G724S, E709K, and V689I in exon 18. The patient responded to, but also showed rapid development of resistance to multiple therapies, including a second-generation EGFR-TKI of afatinib, a platinum-based doublet chemotherapy, and a multiple target TKI of anlotinib. As such, she ended up with a short overall survival time. Further research is required to understand the resistance mechanism(s) of these complex gene mutations. (Source: Chemotherapy)
Source: Chemotherapy - June 28, 2022 Category: Cancer & Oncology Source Type: research
Lung adenocarcinoma harboring triple rare EGFR exon18 mutations rapidly developed resistance to multiple therapies
Non-small cell lung cancer (NSCLC) is the leading cause of cancer related deaths worldwide. Its medical significance has spurred broad investigations into its treatment and prognosis. Shortly after the oncogenic driver mutations were identified, targeted therapies for NSCLC developed rapidly, including the discovery of tyrosine kinase inhibitors (TKIs). Epidermal growth factor receptor TKIs (EGFR-TKIs) have revolutionized the treatment era of NSCLC with common EGFR mutations, especially for non-smoking Asian women. However, it is challenging to tackle NSCLC harboring uncommon mutations, particularly the co-existence of rar...
Source: Chemotherapy - June 28, 2022 Category: Cancer & Oncology Source Type: research
How I Treat Localized Soft Tissue Sarcomas: Update on Diagnosis, Risk Stratification, and Treatment
Background: Adult-type soft tissue sarcomas (STSs) are rare tumors representing about 1% of all adult malignant tumors. Their extreme histological heterogeneity places them among the most challenging fields of diagnostic pathology. The variability of clinical and prognostic presentation between the various histotypes reflects the different management that should be followed on a case-by-case basis. These features make STSs the case in point of how important it is a centralized and multidisciplinary approach.Summary: Surgery represents the mainstay in the treatment of localized STSs. Recently, more and more studies are maki...
Source: Chemotherapy - June 21, 2022 Category: Cancer & Oncology Source Type: research
How I treat localized soft tissue sarcomas: update on diagnosis, risk-stratification and treatment
Background: Adult-type soft tissue sarcomas (STS) are rare tumors representing about 1% of all adult malignant tumors. Their extreme histological heterogeneity places them among the most challenging fields of diagnostic pathology. The variability of clinical and prognostic presentation between the various histotypes reflects the different management that should be followed on a case-by-case basis. These features make soft tissue sarcomas the case in point of how important it is a centralized and multidisciplinary approach.
Summary: Surgery represents the mainstay in the treatment of localized soft tissue sarcomas. Recentl...
Source: Chemotherapy - June 21, 2022 Category: Cancer & Oncology Source Type: research
Paraneoplastic Demyelinating Inflammatory Neuropathy Revealing Metastatic Seminoma: A Case Report
We report the case of a 36-year-old man with unremarkable medical history and no comorbidities who was diagnosed with a retroperitoneal metastatic seminoma. The patient ’s general condition deteriorated, and he developed progressive neurological palsy without other clinical anomalies. Electromyography revealed demyelinating, non-lengthy neuropathy. Guillain-Barré syndrome was initially suspected. However, a positron emission tomography scan revealed a retroperit oneal mass, and blood markers revealed increased human chorionic gonadotropin. The patient was diagnosed with PNS, and a computed tomography-guided biopsy revea...
Source: Chemotherapy - June 14, 2022 Category: Cancer & Oncology Source Type: research
Circular RNA hsa_circ_0068252 functions in cisplatin resistance and immune response via miR-1304-5p/PD-L1 axis in non-small cell lung cancer
Conclusion: The circ_0068252/miR-1304-5p/PD-L1 signal axis participates in the regulation of DDP resistance and immune escape of NSCLC cells. Our results suggest that circ_0068252 may be a potential diagnostic marker and therapeutic target for DDP-resistant NSCLC. (Source: Chemotherapy)
Source: Chemotherapy - June 1, 2022 Category: Cancer & Oncology Source Type: research
